Regeneus: Receives $4M loan with Directors help
- Directors of regenerative medicine company Regeneus (RGS) have also organised a $4 million loan facility
- Then the funds set to help commercialise its Progenza therapy technology for knee osteoarthritis in Japan
- Progenza made from stem cells and has shown strong therapeutic benefits
- It works by reducing inflammation and repairing damaged or diseased tissue
- Of the $4 million, $2 million comes from CEO Leo Lee
- At market close, Regeneus is down 7.02 per cent and trading at 5.3¢ per share
